Zepbound, Lilly and Mounjaro
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning to compounding pharmacies that make cheaper copies of Zepbound, since the branded treatment has been too costly and, up until recently, has been in shortage.
Eli Lilly, Share price
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback